Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling

• Published in: Clinical cancer research Vol. 30; no. 17; pp. 3798 - 3811
• Main Authors: El Zarif, Talal, Meador, Catherine B, Qiu, Xintao, Seo, Ji-Heui, Davidsohn, Matthew P, Savignano, Hunter, Lakshminarayanan, Gitanjali, McClure, Heather M, Canniff, John, Fortunato, Brad, Li, Rong, Banwait, Mandeep K, Semaan, Karl, Eid, Marc, Long, Henry, Hung, Yin P, Mahadevan, Navin R, Barbie, David A, Oser, Matthew G, Piotrowska, Zofia, Choueiri, Toni K, Baca, Sylvan C, Hata, Aaron N, Freedman, Matthew L, Berchuck, Jacob E
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 03-09-2024
• Subjects: Biomarkers; Epigenetics; Liquid Biopsy; Lung Cancer; Precision Medicine; Precision Medicine and Imaging; Tumor Evolution
• ISSN: 1078-0432; 1557-3265; 1557-3265
• DOI: 10.1158/1078-0432.CCR-24-0466

Histologic transformation to small cell lung cancer (SCLC) is a mechanism of treatment resistance in patients with advanced oncogene-driven lung adenocarcinoma (LUAD) that currently requires histologic review for diagnosis. Herein, we sought to develop an epigenomic cell-free (cf)DNA-based approach to non-invasively detect small cell transformation in patients with EGFR mutant (EGFRm) LUAD.
To characterize the epigenomic landscape of transformed (t)SCLC relative to LUAD and de novo SCLC, we performed chromatin immunoprecipitation sequencing (ChIP-seq) to profile the histone modifications H3K27ac, H3K4me3, and H3K27me3, methylated DNA immunoprecipitation sequencing (MeDIP-seq), assay for transposase-accessible chromatin sequencing (ATAC-seq), and RNA sequencing on 26 lung cancer patient-derived xenograft (PDX) tumors. We then generated and analyzed H3K27ac ChIP-seq, MeDIP-seq, and whole genome sequencing cfDNA data from 1 ml aliquots of plasma from patients with EGFRm LUAD with or without tSCLC.
Analysis of 126 epigenomic libraries from the lung cancer PDXs revealed widespread epigenomic reprogramming between LUAD and tSCLC, with a large number of differential H3K27ac (n=24,424), DNA methylation (n=3,298), and chromatin accessibility (n=16,352) sites between the two histologies. Tumor-informed analysis of each of these three epigenomic features in cfDNA resulted in accurate non-invasive discrimination between patients with EGFRm LUAD versus tSCLC (AUROC=0.82-0.87). A multi-analyte cfDNA-based classifier integrating these three epigenomic features discriminated between EGFRm LUAD versus tSCLC with an AUROC of 0.94.
These data demonstrate the feasibility of detecting small cell transformation in patients with EGFRm LUAD through epigenomic cfDNA profiling of 1 ml of patient plasma.